Kazia Therapeutics (KZIA) announced the sale of all intellectual property and trademarks rights to Cantrixil for $1M. In March 2021, Vivesto licensed the exclusive global development and commercialization rights for Cantrixil from Kazia Therapeutics. Having decided not to pursue development of Cantrixil in ovarian cancer, as originally anticipated under the license, Vivesto is currently exploring Cantrixil preclinically for the treatment of hematological cancers. Cantrixil, a legacy molecule in the Kazia pipeline, is a product candidate consisting of the active molecule, a potent and selective third generation benzopyran SMETI inhibitor named TRXE-002-01, encapsulated in alpha-cyclodextrin.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA:
- Kazia Therapeutics Advances Cancer Drug Development with Strategic Moves and Promising Trial Results
- Kazia Therapeutics: Buy Rating Driven by Dual Potential in GBM and Parkinson’s Disease
- Kazia Therapeutics Awarded Research Grant to Explore Paxalisib’s Potential for Parkinson’s Treatment
- Kazia Therapeutics announces research grant awarded from MJFF
- Maxim starts Kazia Therapeutics at Buy amid ‘positive’ GBM study data